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Abstract
Objectives: Among patients with initially unresectable colorectal cancer liver metastases (CLM), a
subset are rendered resectable following the administration of systemic chemotherapy. This study reports
the results achieved in liver resections performed at a single hepatobiliary referral centre after downsizing
chemotherapy in patients with initially unresectable CLM.
Methods: All liver resections for CLM performed over a 10-year period at the Toronto General Hospital
were considered. Data on initially non-resectable patients who received systemic therapy and later
underwent surgery were included for analysis.
Results: Between January 2002 and July 2012, 754 liver resections for CLM were performed. A total of
24 patients were found to meet the study inclusion criteria. Bilobar CLM were present in 23 of these 24
patients. The median number of tumours was seven (range: 2–15) and median tumour size was 7.0 cm
(range: 1.0–12.8 cm) before systemic therapy. All patients received oxaliplatin- or irinotecan-based
chemotherapy. Fourteen patients received combined treatment with bevacizumab. Negative margin (R0)
resection was accomplished in 21 of 24 patients. There was no perioperative mortality. Ten patients
suffered perioperative morbidity. Eighteen patients suffered recurrence of disease within 9 months. Rates
of disease-free survival at 1, 2 and 3 years were 47.6% [95% confidence interval (CI) 30.4–74.6%], 23.8%
(95% CI 11.1–51.2%) and 19.0% (95% CI 7.9–46.0%), respectively. Overall survival at 1, 2 and 3 years
was 91.5% (95% CI 80.8–100%), 65.3% (95% CI 48.5–88.0%) and 55.2% (95% CI 37.7–80.7%),
respectively.
Conclusions: Liver resection in initially unresectable CLM can be performed with low rates of morbidity
and mortality in patients who respond to systemic chemotherapy, although these patients do experience
a high frequency of disease recurrence.
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Introduction
The rationale for the use of local therapies in the management of
advanced colorectal cancer derives from the recognition that up to
30% of patients with metastatic colorectal cancer have liver-
limited disease.1 Effective local therapy should therefore lead to
improved clinical outcomes in at least a subset of these patients.
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Advances in systemic therapy, with the now routine use of a
variety of cytotoxic and biologic therapies, have led to definite
improvements in the survival of patients with advanced colorectal
cancer.2 However, equivalent benefit has also been attributed to
the increased use of hepatic resections for metastatic disease.3 In
fact, despite the additional options of systemic therapy now avail-
able, the chance of longterm survival for patients with metastatic
colorectal cancer remains low, with reported 5-year survival rates
of <10% with chemotherapy alone.4 Consequently, in patients
with liver-limited stage IV disease, hepatic resection of colorectal
cancer liver metastases (CLM) remains the only potentially cura-
tive option. Contemporary reports demonstrate that patients with
resectable disease demonstrate median overall survival (OS) of
24–42 months, and 3- and 5-year survival rates of 50% and 35%,
respectively, following resection of CLM.5,6
Unfortunately, fewer than 25% of patients with CLM are con-
sidered to be candidates for surgery at the time of diagnosis as a
result of the presence of diffuse bilobar disease, critical vascular
involvement and/or the inability to preserve two contiguous ana-
tomic segments at the time of curative liver resection. Patients with
CLM who are initially considered non-resectable are candidates for
systemic chemotherapy. The goals for these patients refer to the
palliation of symptoms and the prolonging of survival, although
the chance of longterm survival on systemic therapy alone remains
low.4 Nonetheless, the improved tumour control rates realized with
these newer regimens of systemic therapy have led to the develop-
ment of a novel paradigm of neoadjuvant treatment for the
purpose of tumour downsizing to the point of surgical cure.
In an 11-year experience reported by Adam et al., 138 of 1104
non-resectable patients underwent operative management for
CLM with curative intent,7 having demonstrated an adequate
response to chemotherapy. This and other experiences have
shown that modern chemotherapy regimens may in fact downsize
tumours in up to 12.5% of patients with initially unresectable
CLM, rendering them candidates for surgery. These patients dem-
onstrate 5-year OS rates of 33–40%,7–10 but the likelihood of
tumour recurrence remains high. The introduction of biologic
agents, such as the vascular endothelial growth factor (VEGF)
monoclonal antibody, bevacizumab, to oxaliplatin- or irinotecan-
based chemotherapy has increased progression-free survival in
patients with CLM.11,12 Currently, bevacizumab is used selectively
and many patients with initially unresectable CLM are offered
first-line treatment with irinotecan- or oxaliplatin-based chemo-
therapy in combination with bevacizumab.
The aim of this study is to report the results achieved in liver
resection following downsizing chemotherapy in patients with
initially unresectable CLM, performed at a single major hepato-
biliary referral centre.
Materials and methods
All liver resections for CLM performed at Toronto General Hos-
pital (TGH) over a 10-year period from January 2002 to July 2012
were considered. Patients eligible for inclusion in this retrospec-
tive analysis comprised those undergoing liver surgery for CLM,
who were initially considered to be non-resectable and were given
systemic therapy.
For the purposes of the present study, cross-sectional imaging
at the time of CLM diagnosis, including computed tomography
(CT) and magnetic resonance imaging (MRI) scans, were retro-
spectively reviewed by two hepatopancreatobiliary (HPB) sur-
geons unaffiliated with the original case. Criteria for resectability
were based on an intent to preserve two contiguous segments of
the liver and to ensure an adequate functional liver remnant (FLR)
at the time of surgery.
Patient demographics, perioperative details and clinicopatho-
logic factors were collected retrospectively by a trained postgradu-
ate hepatobiliary surgical fellow from paper office charts, hospital
electronic records and from a prospective HPB surgical database.
Death clearances were performed by the Ontario Cancer Registry
to confirm vital status.
This study was approved by the Research Ethics Board, Univer-
sity Health Network, Toronto, Ontario, Canada.
Statistical analysis
Outcomes of interest in this study included perioperative results,
disease-free survival (DFS) and OS. Disease-free survival was
defined as the time from liver resection to the date of radiographic
disease recurrence among patients in whom a negative margin
(R0) resection was achieved. Overall survival was defined as the
time from hepatic resection to the date of death or last follow-up.
Subgroup analyses referred to DFS and OS in patients who
received bevacizumab along with oxaliplatin- or irinotecan-based
chemotherapy, compared with patients who received chemo-
therapy only.
Descriptive statistics and frequency tables were used to summa-
rize perioperative results. The Kaplan–Meier method was used to
estimate DFS and OS. Outcomes in patients who received bevaci-
zumab along with oxaliplatin- or irinotecan-based chemotherapy
were compared with those in patients who received chemotherapy
only using the log-rank test and Cox proportional hazard
regressions.
Results
From January 2002 to July 2012, a total of 754 liver resections were
performed at TGH for the treatment of CLM. All patients under-
went resection of the colorectal primary malignancy prior to the
resection of liver metastases. In this group, 31 patients (4.1%)
were initially considered to be non-resectable either as a result of
their tumour burden or for reasons of vascular involvement, but
became candidates for surgery after treatment with combination
systemic therapy.
An independent review of baseline imaging demonstrated that
seven of these 31 patients were likely to have been resectable at
presentation; data for these patients were therefore excluded from
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the analysis. These patients had begun chemotherapy, usually
before surgical referral, had been classified as non-resectable by
the attending surgeon and had been entered as such in the HPB
database.
Patient demographics
The cohort for analysis included 24 patients with a median age of
59.5 years (range: 28–87 years), 20 of whom presented with syn-
chronous disease. A total of 23 patients had diffuse bilobar disease.
One patient with unilobar disease was initially considered to be
non-resectable as a result of the encasement of the inferior vena
cava. The median number of liver metastatic lesions was seven
(range: 2–15); the median size of metastatic lesions was 7.0 cm
(range: 1.0–12.8 cm). Median serum carcinoembryonic antigen
(CEA) was 20.4 mg/l (range: 1.8–690.2 mg/l). Only two patients
had extrahepatic metastatic disease at the time of diagnosis. Both
of these had pulmonary metastases, which were also considered
resectable with curative intent (Table 1).
Systemic therapy
Details of systemic therapy were available for 21 of the 24 patients
(Table 2). All of these patients received chemotherapy based on
5-fluorouracil which included either irinotecan (n = 13) or oxali-
platin (n = 6), or both (n = 2). Of the two patients who received
both oxaliplatin and irinotecan, one required two lines of sequen-
tial therapy and the other was treated with a combination that
included both drugs (IROX). In 14 patients, chemotherapy was
combined with bevacizumab, whereas eight patients received
cytotoxic therapy alone. Two patients were treated on a placebo-
controlled clinical trial which included an anti-angiogenic.
Resectability in these 24 patients was rendered after verification
of a response to chemotherapy based on tumour downsizing,
allowing critical inflow and outflow vascular sparing and the pres-
ervation of two contiguous liver anatomic segments in a single-
stage or a two-stage approach.
Surgical outcomes
A total of 27 liver resections were performed. These included 21
major hepatectomies (four or more Couinaud segments) and six
minor resections (fewer than three Couinaud segments). The
median estimated blood loss was 650 ml (range: 200–6800 ml). A
curative intent resection was accomplished in 21 patients, includ-
ing five who required concomitant radiofrequency ablation
(RFA).
Preoperative portal vein embolization was required in three
patients. A two-stage procedure was planned for five patients;
however, two did not complete the second resection as a result of
tumour progression in the interval following the first-stage pro-
cedure (Table 3). The third patient in whom an R0 resection was
not achieved was scheduled for RFA of a remaining lesion after
hepatectomy, but experienced tumour progression before RFA
was completed.
Table 1 Patient demographics and tumour characteristics in
patients resected for initially unresectable colorectal liver metas-
tases downsized by systemic chemotherapy
Patients, n 24
Age, years, median (range) 59.5 (28–87)
Sex, male, n 12
Primary tumour, n
Colon 19
Rectum 5
Number of metastases, median (range) 7 (2–15)
Size of metastases, cm, median (range) 7.0 (1.0–12.8)
Bilobar disease, n 23
Carcinoembryonic antigen, ng/ml, median (range) 20.4 (1.8–690.2)
Extrahepatic disease, n
Lung 2
Table 2 Details of systemic therapy in patients resected for initially
unresectable colorectal liver metastases downsized by systemic
chemotherapy (n = 24)
Type of therapy Patients, n
Cytotoxic
5-fluorouracil 24
Oxaliplatin 7
Irinotecan 13
Oxaliplatin and irinotecan 2
Unknown 2
Anti-angiogenic
Bevacizumab 14
None 8
Unknown 2
Treatment on clinical trial 2
Lines of systemic therapy, n
1 23
2 1
Table 3 Surgical outcomes in patients resected for initially unresect-
able colorectal liver metastases downsized by systemic chemo-
therapy (n = 24)
Operative procedure, n
Major hepatic resection (4 segments) 21
Minor hepatic resection (<4 segments) 6
Total 27
Curative resection (R0), n 21/24
Preoperative portal vein embolization, n 3/24
Two-stage surgery, n 5/24
Combined radiofrequency ablation, n 5/24
Estimated blood loss, ml, median (range) 650 (200–6800)
Hospital stay, days, median (range) 7 (4–53)
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The median hospital stay was 7 days (range: 4–53 days). Peri-
operative morbidity within 60 days occurred in 10 patients. Com-
plications included three bile leaks (managed with percutaneous
drainage), one subcapsular bleed and one pleural effusion
(Table 4). There were no reoperations for perioperative morbidity.
Perioperative mortality at 60 days was zero.
Survival analysis
Median follow-up was 18.8 months (range: 4–102 months); no
patients were lost to follow-up. Median OS was 56.8 months.
Of the 21 patients in whom an R0 resection was achieved, 18
suffered disease recurrence, of which eight died. The median time
to recurrence in these R0 patients was 8.9 months (range: 2.0–55.3
months).
Sites of recurrence were liver only (n = 6), lung only (n = 5), liver
and lung (n = 5), the peritoneal cavity (peritoneal carcinomatosis)
(n = 1) and the mediastinum (n = 1).
Median DFS at 1, 2 and 3 years was 47.6% [95% confidence
interval (CI) 30.4–74.6%], 23.8% (95% CI 11.1–51.2%) and
19.0% (95% CI 7.9–46.0%), respectively. Median OS at 1, 2
and 3 years was 91.5% (95% CI 80.8–100%), 65.3% (95% CI
48.5–88.0%), and 55.2% (95% CI 37.7–80.7%), respectively
(Figs 1 and 2).
Subgroup analysis demonstrated differences in outcome
between patients treated with a regimen containing bevacizumab
and those treated with cytotoxic agents alone. Median DFS in
patients treated with bevacizumab was 8.9 months, whereas in
those who did not receive the anti-angiogenic agent was 25.6
months [log-rank test, P = 0.025; hazard ratio (HR) 3.6, 95% CI
1.1–12.0; P = 0.033]. There was no significant difference in OS
(log-rank test, P = 0.583; HR 1.4, 95% CI 0.4–5.2; P = 0.585).
Discussion
Surgery for CLM now represents the standard of care, providing
clinical benefit, longterm survival and a cure in 10–25% of
patients who present with resectable disease.13,14 By contrast, the
management of patients with unresectable CLM is largely
restricted to systemic therapy.
The current study adds to an increasing body of literature sup-
porting the use of ‘rescue surgery’, defined as definitive surgery in
patients originally deemed to be non-resectable prior to treatment
Table 4 Postoperative complications in patients resected for initially
unresectable colorectal liver metastases downsized by systemic
chemotherapy (n = 24)
Patients, n
Complication grade
(Dindo–Clavien)
I 2
II 5
IIIa 3
IIIb 0
IV 0
V 0
Complication type
Bile leak 3
Subcapsular bleed 1
Pleural effusion 1
Pneumonia 1
Wound infection 1
Urinary tract infection 2
Abdominal pain 1
Total, n 10/24
0.0
0.2
0.4
0.6
0.8
1.0
Months
D
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Figure 1 Disease-free survival in patients resected for initially
unresectable colorectal liver metastases downsized by systemic
chemotherapy
0.0
0.2
0.4
0.6
0.8
1.0
Months
O
ve
ra
ll 
su
rv
iv
al
0
At risk, n 24 24 21 17 15 15 10
6 12 18 24 30 36
Figure 2 Overall survival in patients resected for initially
unresectable colorectal liver metastases downsized by systemic
chemotherapy
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with chemotherapy. It reports a 10-year clinical experience at a
single high-volume centre and demonstrates a median OS of 56.8
months following conversion surgery, with 2- and 3-year survival
rates of 65.3% and 55.2%, respectively. These results are consistent
with prior reports in similar patient populations using equivalent
neoadjuvant strategies.5,6
One clear limitation of this study refers to its lack of an appro-
priate control group in the form of a cohort of patients with good
tumour control, treated with systemic therapy, who did not
proceed to definitive surgery. It is therefore difficult to attribute
the perceived improvement in survival solely to the ability to
complete surgical resection. Historical controls suggest that
patients with advanced disease managed with chemotherapy
alone have a 3-year OS of <10% and that there are no 5-year
survivors.15–18 It is therefore reasonable to extrapolate that, in this
and other series, clinical benefit is a partial consequence of the
surgical procedure itself and is not solely attributable to a tumour
response to systemic therapy that renders a patient operable. In
this context, however, any comparison with historical controls
should carry the caveat that evolutions in clinical practice with the
incorporation of novel (and targeted) therapies in the manage-
ment of advanced disease and improved supportive care have also
contributed to improved outcomes in contemporary patient
cohorts.
Despite good rates of OS, DFS was still relatively low (23.8% at
2 years and 19.0% at 3 years), but was, again, comparable with
DFS rates established in prior reports, notably by Adam et al., who
reported a tumour recurrence rate of 80% and 5-year DFS of
17%.7
The current data parallel previously published outcomes in
patients with initially resectable CLM who proceeded straight to
surgery. Nanji et al. reported a total of 320 patients with initially
resectable CLM who were treated with upfront surgery and dis-
played median DFS and OS of 19.0 months and 35.1 months,
respectively.19 A retrospective study by Nordlinger et al.20 demon-
strated recurrent disease in over two-thirds of patients who
underwent surgery for resectable CLM. Therefore, these findings
suggest that the majority of patients who are submitted to surgery
following conversion therapy in whom an R0 resection is achieved
are not usually ‘cured’ of disease despite the survival benefit con-
ferred by resection. This supports the notion that CLM should be
treated as a ‘chronic’ disease in some cases. Furthermore, data also
suggest that patients with unresectable CLM who are rendered
candidates for surgery by downsizing chemotherapy can expect a
prognosis comparable with that of patients who present with
initially resectable CLM, as originally shown by Adam et al.7
The vast majority of patients in the present study in whom R0
resections were achieved experienced disease recurrence, with a
median DFS of 8.9 months. These data suggest that even with
current approaches and despite the achievement of R0 resections,
residual microscopic disease remains and ultimately leads to treat-
ment failure. Further improvement in clinical outcomes will
depend on improvements in imaging that facilitate the detection
of even smaller metastases and the incorporation of more effica-
cious systemic therapies. There is ongoing work evaluating the
addition of novel targeted agents to chemotherapy in the periop-
erative management of CLM. Van Cutsem et al. demonstrated the
feasibility of this strategy using a combination of FOLFIRI [folinic
acid (leucovorin), fluorouracil (5-FU), irinotecan hydrochloride]
and the epidermal growth factor receptor (EGFR) monoclonal
antibody, cetuximab, and noted improved rates of metastatic
resection, but stable clinical outcomes.21 Again, given the hetero-
geneity of tumour biology and clinical outcomes, prospective
studies are required to definitively address these issues.
In the present study, no patients were treated with regimens
containing cetuximab or panitumumab as part of downsizing
therapy. This is pertinent as both EGFR-targeting antibodies are
approved for use in metastatic disease. However, because current
government funding restrictions in Ontario, Canada, limit the use
of EGFR-directed therapies to the third-line setting after progres-
sion on both irinotecan- and oxaliplatin-based regimens, or
within the confines of an approved clinical trial, this was not a
component of the systemic therapy of patients included in this
analysis.
Approximately half of the patients were treated with periopera-
tive bevacizumab, which allowed for the examination of the
potential impact of this anti-angiogenic on acute complication
rates and DFS. During the study period, bevacizumab was used
selectively with irinotecan-based chemotherapy. Although some
statistically significant differences were noted, this analysis is
limited by power and selection bias. The trend towards inferior
clinical outcomes in the bevacizumab-treated cohort may be
explained by the omission of anti-angiogenic therapy in patients
who were considered to be more likely to be rendered resectable
after a short course of systemic therapy and included among
patients who were either considered for palliative care only or to
have a low likelihood of becoming resectable. Patients who may
have been considered less likely to demonstrate downsizing in
response to systemic therapy were treated with an optimal
regimen of palliative chemotherapy for advanced disease with
bevacizumab.
The focus of analysis in this study concerned outcomes in ini-
tially non-resectable patients who were converted to resectable
status by systemic chemotherapy. Hence, this is a highly selected
patient population and therefore it is not possible to comment on
the proportion of initially non-resectable patients rendered
resectable, or the efficacy of specific chemotherapy regimens in
achieving conversion. In addition, the potential contributions of
postoperative chemotherapy and systemic therapy for recurrent
disease were considered to lie beyond the scope of this study.
Nonetheless, these factors are certainly crucial to better character-
izing DFS and OS in this patient cohort and remain the focus of
ongoing work.
Morbidity rates in this study were acceptable and consistent
with those reported previously. There were no perioperative
mortalities at 60 days despite the high proportion of major
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hepatectomies. Furthermore, the majority of perioperative mor-
bidities in this cohort were minor and none required an intensive
care unit admission or repeat surgery.
In summary, the results of this study demonstrate that surgical
resection following chemotherapy for initially unresectable CLM
confers good OS compared with the historical survival of patients
treated with chemotherapy alone; however, this does not lead to
cure in the majority of patients. Although the present study is
limited by the inherent biases of a retrospective design, its findings
suggest that initially unresectable CLM treated with systemic
chemotherapy followed by surgery with curative intent is feasible
and is associated with acceptable rates of perioperative morbidity
and mortality. The selection of the most effective chemotherapeu-
tic regimen and potentially suitable candidates for surgery remain
challenging and justify the call for future prospective randomized
trials, and germline and somatic genetic cataloguing to resolve
these key issues.
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